Question 1

Does Barclays own KNTE stock?

Accepted Answer

As of its Q1 2024 13F, Barclays held 14,185 shares of KNTE (Kinnate Biopharma), worth $37,732.

Question 2

How many shares of KNTE does Barclays own?

Accepted Answer

As of its Q1 2024 13F, Barclays held 14,185 shares of KNTE (Kinnate Biopharma).

Question 3

What is Barclays' KNTE position worth?

Accepted Answer

As of its Q1 2024 13F, Barclays' KNTE position was worth $37,732.

Question 4

When did Barclays first buy KNTE?

Accepted Answer

Barclays first reported KNTE in its Q2 2022 13F and listed it in 8 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2024-Q2 Latest	Exited	0	-100.0%	$0	0.0%	—	0
2024-Q1	Decreased	14,185	-2.6%	$37,732	0.0%	—	0
2023-Q4	Unchanged	14,568	0.0%	$34,526	0.0%	—	0
2023-Q3	Unchanged	14,568	0.0%	$20,395	0.0%	—	0
2023-Q2	Decreased	14,568	-50.5%	$44,141	0.0%	—	0
2023-Q1	Increased	29,425	+20.7%	$183,907	0.0%	—	27
2022-Q4	Increased	24,386	+58.1%	$148,755	0.0%	—	32
2022-Q3	Decreased	15,424	-1.5%	$185,000	0.0%	—	0
2022-Q2	New	15,652	-	$197,000	0.0%	—	32

KNTE9 quarters

KNTE
9 quarters